Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 102, P. 106322 - 106322
Published: Oct. 24, 2024
Language: Английский
Frontiers in Pharmacology, Journal Year: 2025, Volume and Issue: 15
Published: Jan. 6, 2025
Glioblastoma (GBM) remains one of the most aggressive and treatment-resistant brain tumors, necessitating innovative therapeutic approaches. Polymer-based nanotechnology has emerged as a promising solution, offering precise drug delivery, enhanced blood-brain barrier (BBB) penetration, adaptability to tumor microenvironment (TME). This review explores diverse applications polymeric nanoparticles (NPs) in GBM treatment, including delivery chemotherapeutics, targeted therapeutics, immunotherapeutics, other agents for radiosensitization photodynamic therapy. Recent advances multifunctional polymer highlight their potential overcome challenges that brought, such heterogeneity tumor, BBB limitation, immunosuppressive TME, consideration biocompatibility safety. Meanwhile, future directions address these are also proposed. By addressing obstacles, polymer-based represents transformative strategy improving treatment outcomes, paving way more effective patient-specific therapies.
Language: Английский
Citations
2
Cancer Nanotechnology, Journal Year: 2025, Volume and Issue: 16(1)
Published: Jan. 17, 2025
Emphasizing the significance of cancer-associated fibroblasts (CAFs), non-malignant yet pivotal players within tumor microenvironment (TME), this review illuminates role inflammatory subtype (iCAF) as catalysts in cancer proliferation, metastasis, and therapeutic resistance. Given their paramount importance, targeting CAFs emerges a robust strategy evolving landscape immunotherapy. Nanomaterials, distinguished by unique features malleability, hold considerable promise biomedicine, especially precision-oriented domain therapy. Their aptitude for modulating immune responses, amplifying drug efficacy through precise delivery, discerningly focusing on cells TME situates nanomaterials formidable tools to transcend boundaries set conventional treatments. This scrutinizes convoluted interplay among CAFs, cells, TME. It further showcases widely utilized management. We underscore potential nanoscale delivery systems directed at underscoring transformative power revolutionizing therapies, enhancing precision, culminating improved patient outcomes.
Language: Английский
Citations
2
Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 2975 - 2975
Published: Aug. 27, 2024
Malignant gliomas present great difficulties in treatment, with little change over the past 30 years median survival time of 15 months. Current treatment options include surgery, radiotherapy (RT), and chemotherapy. New therapies aimed at suppressing formation new vasculature (antiangiogenic treatments) or destroying formed tumor (vascular disrupting agents) show promise. This study summarizes existing knowledge regarding processes by which glioblastoma (GBM) tumors acquire resistance to antiangiogenic treatments. The discussion encompasses activation redundant proangiogenic pathways, heightened cell invasion metastasis, induced hypoxia, creation vascular mimicry channels, regulation immune microenvironment. Subsequently, we explore potential strategies overcome this resistance, such as combining other methods, personalizing treatments for each patient, focusing on therapeutic targets, incorporating immunotherapy, utilizing drug delivery systems based nanoparticles. Additionally, would like discuss limitations methods future directions enhance beneficial effects patients GBM. Therefore, review aims research outcome GBM provide a more promising opportunity thoroughly exploring mechanisms investigating novel strategies.
Language: Английский
Citations
11
Materials Today Bio, Journal Year: 2024, Volume and Issue: 28, P. 101222 - 101222
Published: Sept. 1, 2024
Efficient drug delivery across the blood-brain barrier is imperative for treating glioblastoma (GBM). This study utilized GBM cell membrane to construct a biomimetic targeted nanosystem (GMNPs@AMD/RAPA) that hierarchically releases CXCR4 antagonist AMD3100 and mTOR pathway inhibitor rapamycin (RAPA) reprogramming tumor immune microenvironment suppressing progression of GBM. By initially inhibiting CXCL12/CXCR4 axis, (TME) was reprogrammed enhance infiltration cytotoxic T lymphocytes (CTLs) into TME while survival, proliferation, angiogenesis. Subsequently, through further cellular uptake degradation nanoparticles, RAPA released, progression. successfully combined chemotherapy immunotherapy, achieving effective synergistic therapeutic effects,
Language: Английский
Citations
3
Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 102, P. 106322 - 106322
Published: Oct. 24, 2024
Language: Английский
Citations
2